Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Moyamoya syndrome causing stroke in young women with type 1 diabetes
TL;DR: The importance of recognizing moyamoya syndrome in patients with pre-existing autoimmune diseases such as type 1 diabetes, as prompt diagnosis and treatment can have major impact on patient outcome and quality of life is highlighted.
14
Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
Larry A. Weinrauch,Larry A. Weinrauch,John A. D'Elia,Peter V. Finn,Eldrin F. Lewis,Akshay S. Desai,Brian Claggett,Mark E. Cooper,Janet B. McGill +8 more
TL;DR: It is suggested that evaluation of studies similar to TREAT will assist in determining the optimal therapeutic regimens for populations with moderate to severe renal dysfunction, a condition in which repeated hospitalizations for fluid overload/heart failure add to the high cost of diabetes care.
14
Erratum: Repaglinide vs. Nateglinide Metformin Combination Study Group: Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin (Diabetes Care (2003) 26 (2063-2068))
Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short‐acting GLP‐1 analogue versus progression to basal‐bolus therapy
Irl B. Hirsch,John B. Buse,John Jack Leahy,Janet B. McGill,Anne L. Peters,Helena W. Rodbard,Richard R. Rubin,Jay S. Skyler,Carol A. Verderese,Matthew C. Riddle +9 more
TL;DR: This article considers how the addition of a glucagon‐like peptide 1 (GLP‐1) analogue to basal insulin may provide new opportunities at this stage of treatment, especially for patients concerned about weight gain and risk of hypoglycaemia.
12
Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus.
Janet B. McGill,Anne L. Peters,John B. Buse,Susanne Steiner,Tiffany S. Tran,Frank Pompilio,David M. Kendall +6 more
TL;DR: Pulmonary safety assessment of the TI inhalation system did not identify any safety issues in individuals with either T1DM or T2DM.